Molecular Internal Medicine

Clinical Science

HuR-ry up: How hydrogen sulfide protects from atherosclerosis
M. Barton, M.R. Meyer
Circulation 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018


Iron substitution in the treatment of chronic heart failure.
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 2017 23;147:w14453


Hypertrophe und dilatative Kardiomyopathie
M.R. Meyer, F.R. Eberli.
Swiss Medical Forum 2018;18:168–177

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018


GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton

J Steroid Biochem Mol Biol 176, 82-87, 2018


Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018


Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017



Obesity causes lymphatic vascular injury: time for clinical translation
M. Barton, M. Husmann
J Physiol (Lond) 594, 6807-6808, 2016


Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016


Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016


Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016


Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016


Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015


Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015


Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014


Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014


Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014


In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014


Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014


Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014


Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura

Cardiol Rev 24, 124-220, 2013


Alike but not the same: Anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz

J Cardiovasc Pharmacol 62, 22-25, 2013


Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013


Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton

IFAVA Scientific Newsletter 75, 1, 2013


Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton

Curr Opin Pharmacol 13, 149-153, 2013


Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton

Curr Opin Lipidol 24, 214-220, 2013


Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton

IFAVA Scientific Newsletter 75, 1, 2013


Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton

Life Sci 91, 528-539, 2012


Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer

Hypertension 59, 1011-1103, 2012


Endothelin and the podocyte
M. Barton, P.L. Tharaux

Clin Kidney J 5, 17-27, 2012


Childhood obesity: a life-long health risk
M. Barton

Acta Pharmacol Sin 33, 189-193, 2012


Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012


GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton

Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011


The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton

Nature Rev Endocrinol 7, 715-726, 2011


Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan

Contrib Nephrol 172, 255-260, 2011


Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux

Contrib Nephrol 172, 120-138, 2011


Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012


Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton

Contrib Nephrol 172, 210-222, 2011


Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011


The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton

Nature Rev Endocrinol 7, 715-726, 2011


Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011


Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010


Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010


Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010


Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010


Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009


Morbus Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B. Senn
Swiss Medical Forum 9, 487-488, 2009


Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008


Schwere Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I. Bopp-Kistler
Praxis (Bern 1994) 97, 1137-1141, 2008


Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007


Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007


Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007


WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J e-pub, rapid response August 28, 2007


Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007


Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007


Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society , Online Publication Sept 3, 2007


Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007


Postural effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K. Franzeck
J Vasc Res 43, 321-326, 2006


Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg  44, 993-997, 2006


Spotlight issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005


Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Biochem Biophys Res Commun 295, 1057-61, 2002


Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002


Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002


Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.).
Proceedings of the 5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002


Assessment of coronary flow reserve by contrast-enhanced second harmonic echo Doppler
R. Jenni, A. Linka, M. Barton
Circulation 101, e100, 2000


Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S. Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation 102, III188 -III193, 2000


Doppler mirror image artifacts mimicking mitral regurgitation in patients with mechanical bileaflet mitral valve prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R. Jenni
Eur Heart J Cardiovasc Imag 1, 138-43, 2000


17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998


Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997


Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993


Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993


17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993


Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992